VIRAL VECTORS AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS, IN PARTICULAR RESTENOSIS

Abstract: The present invention relates to defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.

Description: VIRAL VECTORS AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS. IN PARTICULAR RESTENOSIS The present invention relates to a novel, particularly efficacious method for treating pathologies associated with hyperproliferative disorders by means of gene therapy. The method according to the invention consists, more especially, in specifically blocking proliferation of the vascular smooth-muscle cells (VSMC) by means of the in-vivo transfer of the gax gene. The method of the invention is very particularly suited to the treatment of post-angioplastic restenosis by means of overexpressing the gax gene in the vascular wall. According to the present invention, the gax gene can be transferred by means of viral vectors. These vectors are preferably adenoviral vectors. Various genes have been isolated which are linked to the arrest of cell division. Thus, the gas (growth-arrest specific : gas 1-6) and gadd (growth-arrtst and DNA damage- inducible : gadd34, gadd45 and gaddl53) genes are strongly expressed in quiescent cells, that is cells which are blocked in the GO phase of the cell cycle (Schneider et al. , Cell 1988, 54; 787-793, Del Sal et al. , Cell 1992, 12: 3514-3521; Cowled et al. , Exp.Cell.Res . 1994, 211 : 197-202; Brancolini and Schneider, J.Cell.Biol. 1994, 124 : 743-756; Zhan et al. , Mol.Cell.Biol. 1993, 13 : 4242-4250; Jackman et al. , Cancer Res. 54 : 5656-5662, 1994) . In agreement with these findings on gene expression, microinjection of the gas-1 protein blocks the synthesis of DNA (Del Sal et al . , Cell, 1992, 70 : 595-607) . Conversely, the addition of growth factors such as PDGF (platelet-derived growth factor) or foetal calf serum decreases the expression of these genes in in-vitro models (Coccia et al . Mol.Cell.Biol . 1992, 12 : 3514-3521) . This specificity of expression in relation to the state of cell proliferation also appears to have its counterpart in vivo. Thus, the gas-1 gene is strongly expressed in the rat uterus following ovariectorπy (Ferrero and Cairo, Cell.Biol .Int. 1993, 17, 857-862) . In this same animal model, treatment with oestrogens results in a cell proliferation which is reflected, within the uterus, in an increase in the expression of the proto-oncogene c-myc and by a decrease in the expression of the gas-1 gene. Similarly, in an hepatic model of proliferation/regeneration, expression of the gas-6 gene is strongly reduced four hours after partial heptatectomy, i.e. in the period of transition from GO to Gl; this expression returns to normal, probably once division of the hepatocytes has been initiated (Ferrero et al. J.Cell.Physiol. 1994, 158:263-269) . The applicant has been interested in a novel gene, i.e. the gax (growth arrest-specific homeobox) gene, and has now demonstrated that this gene possesses properties which are particularly advantageous for use in the gene therapy of hyperproliferative disorders, in particular restenesiε . The gax gene was initially identified in a cDNA library prepared from rat aorta. It encodes a protein of 303 amino acids. Its sequence has been characterized and its cDNA has been cloned (Gorski et al. , Mol.Cell.Biol. 1993, 6, 3722-3733) . The gax gene possesses certain properties which are similar to those of the gas and gadd genes, since it also appears to regulate the G0/G1 transition in the cell cycle. In the same way, the levels of gax mRNA are decreased in the rat VSMCs by a factor of 10 after two hours of exposure to PDGF (Gorski et al., Mol.Cell.Biol . 1993, 6, 3722-3733) . Expression of the gax gene is therefore repressed during the VSMC mitogenic response. One advantage of the method according to the invention lies principally in the specificity of the expression of the gax gene. Thus, in the adult rat, the gax gene is mainly expressed in the cardiovascular (aorta and heart) system. On the other hand, northern blotting has failed to demonstrate the presence of gax mRNA in liver, brain, stomach or skeletal muscle. Post-angioplastic restenesis is a localized hyperproliferative disorder which develops following a non-surgical intervention in the region of the atherosclerotic plaque. Thus, treatment of an atherosclerotic lesion by angioplasty very frequently results (in up to 50% of cases in certain studies) in a restenosis following mechanical injury to the arterial wall . A key event in this mechanism is the proliferation and migration of the vascular smooth-muscle cells (VSMC) of the tunica media towards the tunica intima, in particular due to the absence of protection and/or feedback exercised by the endothelial cells of the tunica intima. The ability selectively to express an antiproliferative gene according to the invention in the VSMC cells represents a very substantial advantage. Another advantage of the method according to the invention also lies in the fact that the gax gene belongs to the family of homeotic genes . These genes encode transcription factors which contain consensus sequences (or homeodomains) which recognize specific regions of the DNA (or homeoboxes) (review : Gehring et al. Cell, 78 : 211-223, 1994) . The homeodomain of the rat gax protein is contained between amino acids 185 and 245. Interestingly, the homeotic genes which have been identified to date are involved in the control of cell differentiation/growth during embryogenesis, thus reinforcing the therapeutic potential of the method according to the invention (review : Lawrence and Morata Cell 78 : 181-189, 1994; Krumlauf, Cell 78 : 191-201, 1994) . The invention relates initially, therefore, to a defective recombinant virus which contains at least one inserted gene encoding all or part of the GAX protein or of a variant of this protein. The invention also relates to the use of such a virus for treating hyperproliferative pathologies. In the viruses of the invention, the inserted gene can be a fragment of complementary DNA (cDNA) or of genomic DNA (gDNA) , or a hybrid construct consisting, for example, of a cDNA into which one or more introns have been inserted. The gene can also consist of synthetic or semi-synthetic sequences. As indicated above, the gene can be a gene encoding all or part of the GAX protein or be a variant of this protein. Within the meaning of the present invention, the term variant denotes any mutant, fragment or peptide which possesses at least one biological property of GAX, as well as any homologue of GAX which is obtained from other species . These fragments and variants may be obtained by any technique known to the person skilled in the art, in particular by genetic and/or chemical and/or enzymic modifications or else by hybridization or by expression cloning, enabling variants to be selected according to their biological activity. The genetic modifications include suppressions, deletions, mutations, etc. Within the meaning of the invention, the inserted gene is preferably the gene encoding all or part of the rat GAX protein or of its human homologue. It is more preferably a cDNA or a gDNA. In general, the inserted gene also includes sequences which enable it to be expressed in the infected cell . These sequences can be sequences which are naturally responsible for expressing the said gene, if these sequences are capable of functioning in the infected cell. The sequences can also be sequences of a different origin (responsible for expressing different proteins or even synthetic proteins) . In particular, the sequences can be sequences of eukaryotic or viral genes or derived sequences which stimulate or repress transcription of a gene in a specific or non-specific manner and in an inducible or non- inducible manner. As an example, they can be promoter sequences which are derived from the genome of the cell which it is desired to infect or from the genome of a virus, in particular the promoters of the adenoviral E1A and MLP genes, the CMV or the LTR-RSV promoter, etc. Eukaryotic promoters which may also be cited are ubiquitous promoters (HPRT, vimentin, actin, tubulin, etc.), intermediate filament promoters (desmin, neurofilaments, keratin, GFAP, etc.), therapeutic gene promoters (MDR type, CFTR, factor VIII, etc.), tissue-specific promoters (actin promoter in smooth muscle cells), promoters which are preferentially activated in dividing cells, or else promoters which respond to a stimulus (steroid hormone receptor, retinoic acid receptor, etc.) . In addition, these expression sequences can be modified by adding activating sequences, regulatory sequences, etc. Otherwise, when the inserted gene does not include any expression sequences, it can be inserted into the genome of the defective virus downstream of such a sequence. Furthermore, the inserted gene generally includes, upstream of the coding sequence, a signal sequence which directs the synthesized polypeptide into the secretory pathways of the target cell. While this signal sequence can be the natural GAX signal sequence, it can also be any other functional signal sequence (that of the gene for thymidine kinase, for example), or an artificial signal sequence. The viruses according to the present invention are defective, that is unable to replicate autonomously in the target cell. In general, the genome of the defective viruses which are used within the scope of the present invention thus lacks at least the sequences which are necessary for the replication of the said virus in the infected cell . These regions can either be eliminated (in whole or in part) , be rendered non-functional or be substituted by other sequences, in particular by the inserted gene. Preferably, the defective virus nevertheless retains the sequences of its genome which are necessary for encapsidating the viral particles. The virus according to the invention can be derived from an adenovirus, from an adeno-associated virus (AAV) or from a retrovirus. According to one preferred embodiment, the virus is an adenovirus. Various serotypes of adenovirus exist, whose structure and properties vary somewhat. Of these serotypes, preference is given, within the scope of the present invention, to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see application W094/26914) . Those adenoviruses of animal origin which can be used within the scope of the present invention and which may be cited are adenoviruses of canine, bovine, murine (example : Mavl, Beard et al., Virology 75 (1990) 81), ovine, porcine, avian or else simian (example : SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus [Manhattan or A26/61 strain (ATCC VR-800), for example] . Preferably, use is made, within the scope of the invention, of adenoviruses of human, canine or mixed origin. Preferably, the defective adenoviruses of the invention comprise the ITRs, an encapsidation sequence and the nucleic acid of interest. Still more preferably, in the genome of the adenoviruses of the invention, at least the El region is non-functional. The viral gene under consideration can be rendered non-functional by any technique known to the person skilled in the art, in particular by total removal, substitution, partial deletion or the addition of one or more bases to the gene(s) under consideration. Such modifications can be achieved in vitro (on the isolated DNA) or in situ, for example using the techniques of genetic manipulation or else by treating with mutagenic agents. Other regions may also be modified, in particular the E3 region (WO95/02697) , the E2 region (W094/28938) , the E4 region (W094/28152, W094/12649 and WO95/02697) and the L5 region (WO95/02697) . According to a preferred embodiment, the adenovirus according to the invention contains a deletion in the El and E4 regions. According to another preferred embodiment, it contains a deletion in the El region into which the E4 region and the sequence encoding GAX are inserted (cf. FR94 13355) . In the viruses of the invention, the deletion in the El region preferably extends from nucleotides 455 to 3329 in the sequence of the Ad5 adenovirus. The defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al . , Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917) . In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid which carries, inter alia, the DNA sequence of interest. The homologous recombination is effected following cotransfection of the said adenovirus and plasmid into an appropriate cell line. The cell line which is employed should preferably (i) be transformable by the said elements, and (ii) contain the sequences which are able to complement the part of the genome of the defective adenovirus, preferably in integrated form in order to avoid the risks of recombination. Examples of cell lines which may be mentioned are the human embryonic kidney cell line 293 (Graham et al. , J. Gen. Virol. 36 (1977) 59) which contains, in particular, integrated into its genome, the left-hand part of the genome of an Ad5 adenovirus (12%), or cell lines which are able to complement the El and E4 functions such as described, in particular, in applications nos. WO 94/26914 and WO95/02697. Subsequently, the adenoviruses which have multiplied are recovered and purified using standard molecular biological techniques, as illustrated in the examples . The adeno-associated viruses (AAV) are DNA viruses of relatively scaled-down size which integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation. Furthermore, they do not appear to be involved in human pathologies . The AAV genome has been cloned, sequenced and characterized. It encompasses approximately 4700 bases and contains an inverted terminal repeat (ITR) region of approximately 145 bases at each end, serving as an origin of replication for the virus . The remainder of the genome is divided into two essential regions which carry the encapsidation functions: the left-hand part of the genome, which contains the rep gene involved in viral replication and expression of the viral genes; and the right- hand part of the genome, which contains the cap gene encoding the capsid proteins of the virus. The use of vectors derived from the AAVs for transferring genes in vitro and in vivo has been described in the literature (see, in particular, WO 91/18088; WO 93/09239; US 4,797,368, US5,139,941, EP 488 528) . These applications describe various AAV-derived constructs in which the rep and/or cap genes are deleted and replaced by a gene of interest, and the use of these constructs for transferring the said gene of interest in vitro (into cultured cells) or in vivo, (directly into an organism) . The defective recombinant AAVs according to the invention can be prepared by cotransfeeting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus) . The AAV recombinants which are produced are then purified by standard techniques. The invention also relates, therefore, to an AAV-derived recombinant virus whose genome encompasses a sequence encoding GAX flanked by the AAV ITRs. The invention also relates to a plasmid encompassing a sequence encoding GAX flanked by two ITRs from an AAV. Such a plasmid can be used as it is for transferring the GAX sequence, with the plasmid, where appropriate, being incorporated into a liposomal vector (pseudo- virus) . The construction of recombinant retroviral vectors has been widely described in the literature: see, in particular, EP 453242, EP178220, Bernstein et al . Genet. Eng. 7 (1985) 235; McCor ick, BioTechnology 3 (1985) 689, etc. In particular, the retroviruses are integrating viruses which infect dividing cells. The retrovirus genome mainly encompasses two LTRs, an encapsidation sequence and three coding regions (gag, pol and env) . In the retrovirus-derived recombinant vectors, the gag, pol and env genes are generally deleted, in whole or in part, and replaced with a /30385 PC17US96/04493 12 heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus such as, in particular, MoMuLV ("murine Moloney leukaemia virus"; also designated MoMLV) , MSV ("murine Moloney sarcoma virus") , HaSV ("Harvey sarcoma virus") ; SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus") or else Friend virus. In general, in order to construct recombinant retroviruses containing a sequence encoding GAX according to the invention, a plasmid is constructed which contains, in particular, the LTRs, the encapsidation sequence and the said coding sequence and is then used to transfeet what is termed an encapsidation cell line, which cell line is able to supply in trans the retroviral functions which are deficient in the plasmid. In general, the encapsidation cell lines are thus able to express the gag, pol and env genes. Such encapsidation cell lines have been described in the prior art, in particular the cell line PA317 (US4, 861, 19) ; the PsiCRIP cell line (WO90/02806) and the GP+envAm-12 cell line (WO89/07150) . In addition, the recombinant retroviruses can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsidation sequences which include a part of the gag gene (Bender et al., J. Virol. 61 (1987) 1639) . The recombinant retroviruses which have been produced are then purified by means of standard techniques. It is very particularly advantageous to use a defective recombinant adenovirus for treating restenosis . Thus, adenoviruses possess a high capacity for infecting proliferating vascular smooth-muscle cells. This allows relatively low quantities of the active principle (recombinant adenovirus) to be used and also results in effective and very rapid action on the sites to be treated. The adenoviruses of the invention are also able to express the introduced gax gene at high levels, thereby conferring on them a very efficient therapeutic action. Furthermore, due to their episomal nature, the adenoviruses of the invention only persist for a limited time in the proliferative cells and therefore have a transitory effect which is perfectly suited to the desired therapeutic effect. The present invention also relates to a pharmaceutical composition which comprises one or more defective recombinant viruses such as previously described. Such compositions can be formulated with a view to administering them by the topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, etc. route. Preferably, the composition according to the invention comprises excipients which are pharmaceutically acceptable for an injectable formulation, in particular for an injection into the vascular wall. These excipients can, in particular, be sterile, isotonic saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, etc., or mixtures of such salts), or dry, in particular lyophilized compositions which, by means of the addition, as the case may be, of sterilized water or physiological saline, allow injectable solutions to be constituted. The excipient can also be a hydrogel which is prepared from any biocompatible or non-cytotoxic (homo or hetero) polymer. Such polymers have been described, for example, in application W093/08845. Certain of them, such as, in particular, those obtained from ethylene and/or propylene oxide are commercially available. In their use for treating pathologies which are linked to hyperproliferative disorders, the defective recombinant adenoviruses according to the invention can be administered in different ways, in particular by means of injection. Preferably, for the treatment of restenesis, the adenoviruses of the invention are administered directly to the blood vessel wall by means of an angioplasty balloon which is coated with a hydrophilic film (for example a hydrogel) which is saturated with the adenoviruses, or by means of any other catheter containing an infusion chamber for the adenoviral solution, which can thus be applied in a precise manner to the site to be treated and allow the adenoviruses to be liberated locally and efficiently at the level of the cells to be treated. This method of administration advantageously makes it possible to infect a high percentage (up to 9.6%) of the cells of the tunica media, which constitute the preferred target for treating restenosis, whereas the standard methods of administration (intravenous injection, for example) do not enable these cells to be infected to any very significant degree. The treatment method of the invention advantageously consists in introducing a composition comprising a hydrogel saturated with recombinant adenoviruses at the site to be treated. The hydrogel can be deposited directly onto the surface of the tissue to be treated, for example during a surgical intervention. Advantageously, the hydrogel is introduced at the site to be treated by means of a catheter, for example a balloon catheter, in particular at the time of angioplasty. In a particularly advantageous manner, the saturated hydrogel is introduced at the site to be treated by means of a balloon catheter. The doses of virus which are used for the injection can be adjusted according to different parameters, in particular according to the mode of administration employed and the desired duration of the treatment. Generally, the recombinant viruses according to the invention are formulated and administered in the form of doses of between 10 ' ' and 10 14 pfu/ml. In the case of AAVs and adenoviruses, doses of from 10° to 10 10 pfu/ml can also be used. The term pfu ( "plaque-forming unit") corresponds to the infective power of a suspension of virions and is determined by infecting an appropriate cell culture and measuring, generally after 48 hours, the number of plaques of infected cells . The techniques for determining the pfu titre of a viral solution are well documented in the literature. The present invention offers a novel and very efficient means for treating or preventing pathologies linked to hyperproliferative disorders such as restenosis. Furthermore, this treatment can relate just as well to humans as to any animals such as sheep, cattle, domestic animals (dogs, cats, etc.), horses, fish, etc. The present invention is more completely described using the examples which follow and which should be considered as being illustrative and not limiting. FIGURE LEGENDS Figure 1 : Depiction of the plasmid pCOl. Fiσure 2 : Depiction of the plasmid pXL-CMV-Gax"*. Figure 3 : Nuclear location of the GAX-HA protein in the VSMCs transfected with pXL-CMV-Gax HA . Figure 3A : VSMCs transfected with vector pCGN (absence of GAX insert) Figure 3B : VSMCs transfected with vector pXL-CMV- Gax^. Figure 4 : Nuclear location of the GAX-HA protein in VSMCs treated with Ad-CMV-Gax. Figure 5 : Effect of Ad-CMV-GAX on the proliferation of VSMCs (t=24 hours) - The VSMCs are counted 24 hours after having been treated with Ad-CMV-Gax (1000 pfu/cell) or with a control adenovirus (Ad- RSV-βGal, 1000 pfu/cell) . Cell growth is blocked (0.5% FCS) or stimulated (FCS 20%) . Figure 6 : Effect of Ad-CMV-GAX on the proliferation of VSMCs (t=48 hours) - The VSMCs are counted 48 hours after having been treated with Ad-CMV-Gax (1000 pfu/cell) or with a control adenovirus (AD- RSV-βGal, 1000 pfu/cell) . Cell growth is blocked (0.5% FCS) or stimulated (FCS 20%) . Figure 7 : Effect of Ad-CMV-Gax on the viability of VSMCs which are incubated in the presence of foetal calf serum (FCS 20%) . - experimental conditions, cf. Figure 6 Figure 7A : cells which are not treated with adenovirus Figure 7B : cells which are treated with Ad-RSV- βGal Figure 7C : cells which are treated with Ad-CMV- Gax Figure 8 : Effects of Ad-CMV-Gax and Ad-RSV-βGal on rat carotid arteries following injury with a balloon catheter. Figure 8A : measurement of intimal surface area Figure 8B : measurement of the ratio of intima to media Figure 8C : measurement of luminal narrowing. Figure 9 Arterial cross sections of control and treated vessels Figure 9A : Ad-RSV-βGal treated control vessels Figure 9B : Ad-CMV-Gax treated vessels . GENERAL MOLECULAR BIOLOGICAL TECHNIQUES The standard methods employed in molecular biology, such as preparative extractions of plasmid DNA, centrifugation of plasmid DNA in a caesium chloride gradient, electrophoresis on agarose or acrylamide gels, purification of DNA fragments by electroelution, extraction of proteins with phenol or with phenol/chloroform, precipitation of DNA in a saline medium using ethanol or using isopropanol, transformation into Eschericia coli, etc. ..., are well known to the person skilled in the art and are amply described in the literature [Maniatis T. et al., "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982; Ausubel F.M. et al. (eds), "Current Protocols in Molecular Biology", John Wiley & Sons, New York, 1987] . Plasmids of the pBR322 and pUC type, and phages of the M13 series were obtained commercially (Bethesda Research Laboratories) . For ligations, the DNA fragments can be separated according to their size by electrophoresis in agarose or acrylamide gels, extracted with phenol or with a phenol/chloroform mixture, precipitated with ethanol and then incubated in the presence of T4 DNA ligase (Biolabs) in accordance with the supplier's recommendations. 5 ' protruding ends can be filled in using the Klenow fragment of E. coli DNA polymerase I (Biolabs) in accordance with the supplier' s specifications. 3 ' protruding ends are destroyed in the presence of T4 DNA polymerase (Biolabs), which is used in accordance with the manufacturer's recommendations. 5' protruding ends are destroyed by careful treatment with SI nuclease. In-vitro site-directed mutagenesis using synthetic oligodeoxynucleotides can be carried out in accordance with the method developed by Taylor et al . [Nucleic Acids Res . 13 . (1985) 8749-8764] employing the kit distributed by Amersham. Enzymic amplification of DNA fragments by means of the technique termed PCR [βolymerase-catalyzed £hain reaction, Saiki R.K. et al., Science 230 (1985) 1350-1354; Mullis K.B. and Faloona F.A. , Meth. Enzym. 155 (1987) 335- 350] can be effected using a DNA thermal cycler (Perkin Elmer Cetus) in accordance with the manufacturer's specifications. Nucleotide sequences can be ascertained by means of the method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA, 71, (1977) 5463-5467] using the kit distributed by Amersha . Example 1 : construction of the vector PXL-CMV- Gax m , carrying the gene encoding the rat gax protein under the control of the CMV promoter. This example describes the construction of a vector which contains the cDNA encoding the gax protein (species : rat) and adenoviral sequences which enable recombination to take place. The epitope of influenza virus haemagglutinin (epitope HAD , encompassing 18 amino acids, is added to the N-terminal end of the gax protein (Field et al., Mol.Cell.Biol. 8 : 2159-2165, 1988) . Adding the epitope in this way enables gax expression to be followed, in particular by immunofluorescence techniques, using antibodies which are directed against the HAl epitope. In addition to its sensitivity, this method at the same time makes it possible to eliminate, both in vitro and in vivo, the background noise corresponding to the expression of endogenous gax proteins. 1.1. Construction of plasmid pCOl A - Construction of plasmid pCE The EcoRl/Xbal fragment corresponding to the left- hand end of the Ad5 adenovirus genome was first of all cloned between the EcoR and Xba sites of the vector pIC19H. This generates plasmid pCA. Plasmid pCA was then cut with Hinfl and its 5 ' protruding ends were filled in using the Klenow fragment of E.coli DNA polymerase I; it was then cut with EcoRI . The fragment of plasmid pCA which was thus generated, and which contains the left-hand end of the Ad5 adenovirus genome, was then cloned between the EcoRI and Smal sites of the vector pIC20H (Marsh et al. , Gene __ (1984) 481) . This generates plasmid pCB. Plasmid pCB was then cut with EcoRI and its 5 ' protruding ends were filled in using the Klenow fragment of E.coli DNA polymerase I; it was then cut with BamHI. The fragment of plasmid pCB which was thus generated, and which contains the left-hand end of the Ad5 adenovirus genome, was then cloned between the Nrul and Bglll sites of vector pIC20H. This generates plasmid pCE an advantageous characteristic of which is that it possesses the first 382 base pairs of the Ad5 adenovirus followed by a multiple cloning site. B - Construction of plasmid pCD' The Sau3A (3346) /Sstl (3645) and Sstl (3645) /Narl (5519) fragments from the genome of the Ad5 adenovirus were first of all ligated together and cloned between the Clal and BamHI sites of vector pIC20H, thereby generating plasmid pPY53. The Sall/Taql fragment from plasmid pPY53 (prepared from a dam- background) , containing the part of the Ad5 adenovirus genome between the Sau3A (3346) and Taql (5207) sites, was then cloned between the Sail and Clal sites of vector pIC20H, thereby generating plasmid pCA 1 . The Taql (5207) /Narl (5519) fragment of the Ad5 adenovirus genome, prepared from a dam- background, and the Sall-Taql fragment from plasmid pCA' were then ligated together and cloned between the Sail and Narl sites of vector pIC20H. This generates plasmid pCC' . The Narl (5519) /Nrul (6316) fragment of the Ad5 adenovirus genome, prepared from a dam- background, and the Sall/Narl fragment of plasmid pCC ' were then ligated together and cloned between the Sail and Nrul sites of vector pIC20R. This generates plasmid pCD' . C - Construction of plasmid pCOl Partially digesting plasmid pCD' with Xhol and then completely digesting it with Sail generates a restriction fragment which contains the Ad5 adenovirus sequence from the Sau3A (3446) site to the Nrul (6316) site. This fragment was cloned into the Sail site of plasmid pCE. This generates plasmid pCOl (Figure 1) , which contains the left-hand part of the Ad5 adenovirus up to the Hinfl (382) site, a multiple cloning site and the Sau3A (3446) /Nrul (6316) fragment of the Ad5 adenovirus. 1.2. Construction of vector pXL-CMV-Gax 1 ^ (cf. Figure 2) The Gax cDNA was cloned between the Xbal and BamHI sites of vector pCGN (Tanaka and Herr, Cell 60 : 375-386, 1990) . The resulting vector, pGCN-Gax, contains the early promoter and enhancer sequence of cytomegalovirus (CMV) (- 522, +72; Boshart et al, Cell, 41 : 521-530, 1985), the leader sequence of herpes simplex virus thymidine kinase, including the AUG initiation codon, as well as the first three amino acids (+55, +104; Rusconi and Yamamoto, EMBO J., 6 : 1309-1315, 1987), the sequence encoding the HAl epitope [Y P Y D V P D Y A S L G G P (SEQ ID No. 1) ] , the rat gax cDNA and, finally, the polyadenylation sequence of the rabbit β- globin gene (Pabo et al, Cell, 35 : 445-453, 1983) . Vector pCGN-Gax was then cut with Xmnl and Sfil and the resulting fragment, containing the promoter, the cDNA and the polyadenylation sequence, was introduced, after first having been treated with Klenow, into the EcoRV site of the shuttle vector pCOl, which contained the adenoviral sequences required for recombination. The plasmid which was obtained was designated pXL-CMV-Gax"* (cf. Figure 2) . Example 2 : demonstration of the proliferation- inhibiting properties of plasmid pXL-CMV-gax-HA. This example describes the operative procedures which can be used to demonstrate, in vitro and at one and the same time, the quality of the homologous recombination vectors (cf. Example 1) as regards expression (detection of the gax protein and the HA epitope) and as regards activity (effect on cell proliferation) . The vascular smooth muscle cells (VSMCs) are cultured by enzymically digesting NZW rabbit aorta using a method adapted from Chamley et al. (Cell Tissue Res. 177 503-522 1977) . Briefly, once having been removed, the rabbit aorta is incubated at 37°C for 45 minutes in the presence of collagenase (collagenase II, Cooper Biomedical) . A second digestion is then carried out for approximately two hours in the presence of collagenase and elastase (Biosys) , thereby giving rise to a cell suspension. The cells are maintained in the presence of 20% foetal calf serum and used for all the tests (cf. below) prior to the tenth passage. In all these experiments, the smooth muscle cells are characterized by immunolabelling by means of anti-αSM actin antibody (F-3777, Sigma) . In order to verify the quality of the expression vectors (cf. Example 1) , the presence and the location of the gax protein are monitored by immunofluorescence for each construct. In order to do this, the smooth muscle cells or the 3T3 cells are transfected with plasmids pXL-CMV-Gax^ and pCGNgax in the presence of a DOSPA/DOPE mixture (Lipofectamine, Gibco BRL) . The cells are incubated in the presence of the DNA/liposome complex in a culture medium lacking foetal calf serum for 4 to 8 hours (optimal duration : 8 hours for the SMCs) . After incubating for 24 hours in the presence of foetal calf serum, the cells are cultured on a microscope slide (Titertek) , with a view to immunofluorescence, for a further 24 hours. The cells are then fixed in the presence of 4% paraformaldehyde and subsequently permeabilized by adding 0.1% triton. After saturating the cells in the presence of bovine serum albumin (BSA, Sigma), anti-HA antibody (12CA5, Boehringer Mannheim) and then fluorescein-conjugated antibody are added in succession. Immunofluorescence experiments carried out simultaneously on NIH3T3 cells and on a primary culture of rabbit VSMCs demonstrate that both plasmid pCGNgax and the "shuttle" plasmid pXL-CMV-Gax^ do indeed encode a protein which is located in the nucleus (cf. Figure 3A control plasmid; 3B : plasmid pXL-CMV-Gax"*) . Furthermore, following extraction of the nuclear proteins from cells transfected with pXL-CMV-Gax™, we were able to demonstrate, by means of western blotting, a protein which is detected with antibodies directed against the HA epitope. The effect of the above vectors on cell proliferation was then ascertained. In order to do this, an indirect method was used which is based on measuring colony formation. Briefly, NIH3T3 mouse embryonic cells were employed to carry out colony-formation tests using a method which was adapted from Schweighoffer et al. (Mol.Cell.Biol. 1993, 13 : 39-43) . Briefly, the cells are cotransfected with a plasmid carrying the gene for resistance to neomycin and with an excess of the vector of interest (pCGNgax or pXL-CMV- Gax"*) . After a period of selection in G418, the colonies are stained with a solution of carbol fuchsin (Diagnostica, Merck) and counted. The results of a representative experiment, which are given in Table 1, demonstrate a decrease in the number of colonies in the case of cells transfected with pCGNgax. Table 1 3T3 cell transfection Number of colonies conditions following selection in G418 pCGN <5μg) + pSV2neo 183±28 (*) (lμg) (§) pCGNgax (5μg) + pSV2neo 93±11 dμg ) (§) pCGN control vector: absence of gax insert (*) p<0.01 Example 3 : Construction of the recombinant adenovirus Ad-CMVgax Vector pXL-CMV-Gax™, which was prepared in Example 1, was subsequently linearized and cotransfected, for recombination, with a deficient adenoviral vector into helper cells (cell line 293) which supplied in trans the functions encoded by the adenovirus El (E1A and E1B) regions. The adenovirus Ad-CMVgax was obtained by means of in-vivo homologous recombination between the adenovirus Ad.RSVβgal (Stratford Perricaudet et al. , J. Clin. Invest 90 (1992) 626) and vector pXL-CMV-Gax"* in accordance with the following protocol: vector pXL-CMV-Gax^, linearized with the enzyme Xmnl, and adenovirus Ad.RSVβgal, linearized with Clal, were cotransfected into cell line 293 in the presence of calcium phosphate in order to enable homologous recombination to take place. The recombinant adenoviruses which were generated in this way were selected by plaque purification. Following isolation, the recombinant adenovirus is amplified in cell line 293, resulting in a culture supernatant which contains the non-purified recombinant defective adenovirus having a titre of approximately 10 10 pfu/ml. The viral particles are purified by centrifugation on a caesium chloride gradient in accordance with the known techniques (see, in particular, Graham et al. , Virology 52 (1973) 456) . The adenovirus Ad-CMVgax is stored at -80°C in 20% glycerol. Example 4 : Demonstration of the proliferation- inhibiting properties of adenovirus Ad-CMVgax. This example describes the experimental procedures which can be used to demonstrate, at one and the same time, the quality of the recombinant adenovirus in terms of gax protein production and in terms of biological activity (effect on cell proliferation) . The rabbit aorta VSMCs are incubated in the presence of adenovirus Ad-CMVgaxHA and a control adenovirus (ad-RSVβGal : recombinant adenovirus expressing β- galactosidase under the control of the RSV promoter) , which is diluted in culture medium (DMEM, 0.5% FCS) . After approximately one hour at 37°C in a moist atmosphere, the medium containing the adenoviral solution is aspirated off and replaced by culture medium (DMEM, 0.5% FCS) for a period of from 18 to 24 hours. The FCS-rich medium (final concentration of FCS 20%) is then added in order to stimulate cell proliferation and the cells are counted 24 hours and 48 hours later. In addition, at 24 hours after adding the adenoviral solution, expression of the gax protein by the VSMCs is monitored by the techniques described in Example 2, namely nuclear labelling by means of immunofluorescence (localization of the protein) and also by western blotting. The protein produced by the recombinant adenovirus is efficiently detected by antibodies recognizing the HA epitope and possesses the same electrophoretic mobility as the gax protein which is detected in the nucleus of VSMCs which are transfected with pCGNgax or pXL-CMV-Gax . Figure 4 illustrates the location of the Gax protein in VSMCs which are incubated in the presence of Ad-CMVgaxHa. The results of a representative experiment, which are shown in Figure 4, demonstrate a marked fall in the number of cells following the addition of Ad-CMVgaxHA virus . On the other hand, this reduction in the number of cells is not observed following treatment with the control adenovirus used at the same concentration (M.O.I. 1000) . We have verified in parallel, by means of immunofluorescence, that this high multiplicity of infection enables either the β-gal marker gene (use of anti- E.Coli. β-gal antibody, Monosan) or the gax protein (use of anti-HA antibody, cf. Example 2) to be expressed in more than 90% of the rabbit VSMC population. Addition of ad-RSV-βgal virus is associated with a weak cytostatic effect (-13%) after culturing for 24 hours in the presence of foetal calf serum (20%) . Under the same experimental conditions, the treatment with Ad-CMVgaxHA leads to a 57% decrease in the number of cells (cf. Figure 5) . The biological activity of the Ad-CMVgaxHa virus is very obviously accentuated after 48 hours of culture, and may even be associated with cell death (cf . Figures 6 and 7) . Thus, the blocking of proliferation which is caused by Ad-CMVgaxHA is associated with a pronounced reduction in the number of cells which can be detected after culturing for a period of 24 hours (cf. Figure 5) . Interestingly, this effect of Ad-CMVgaxHA is observed in cells which are stimulated with a high concentration of FCS (20%) but not in cells which are deprived of FCS (0.5%) (cf. Figure 6) . This example therefore demonstrates that a recombinant adenovirus which encodes the gax protein can block cell division efficiently without having any significant effect on the viability of cells which are blocked in the GO phase of their cycle. The effect of the Ad-CMVgaxHA adenovirus on the viability of VSMCs in culture is also illustrated by Figure 7. The inhibitory properties of Ad-CMVgaxHA on the synthesis of DNA are confirmed by bromodeoxyuridine (BrdU)- incorporation experiments. Briefly, at 24 hours after having added adenovirus, the VSMCs are incubated in the presence of FCS (10 to 20%) and BrdU (10μM), which is incorporated instead of thymine into the cells in the DNA synthesis phase and can be detected with specific antibodies. The BrdU incorporation is quantified by means of flow cytometry. The same flow cytometry methodology can be employed for visualizing the progress made by Ad-CMVgaxHA- treated rabbit VSMCs in their cell cycle. Treatment with Ad- CMVgaxHA is accompanied by blockage of the cell cycle in the G0/G1 phase. Example 5 : In Vivo Inhibition of intimal hvperplasia using an adenovirus-gax. This example shows the efficacy of recombinant adenoviruses in a model of vascular pathology. The model of arterial lesion used rests upon an abrasion of rat carotid (Clows et al. , Lab Inverst 49 (1983) 327-333) . In this model, VSMCs dedifferentiate, proliferate and migrate to form a neointima that can partially occlude the artery within two weeks of the injury. Sprague-Dawley rats were anesthesized by intraperitoneal injection of pentobarbital (45 mg/kg) . Following external carotid arterioto y, rat carotid arteries were denuded with a balloon catheter and exposed to 1.10 * pfu of Ad-CMVgaxHA or Ad-RSVβ-Gal. The adenovirus is used in a solution containing 15% poloxamer 407, which facilitates the adenovirus gene transfer. Following a twenty minute incubation, the virus solution was withdrawn and the ligatures were removed to restore circulation. Rats were sacrificed two weeks later and quantitative morphometric analyses were performed on cross sections of the treated vessels . The results are presented in Figures 8 and 9. The results obtained show that all nine Ad-RSVβ- Gal transfected carotid arteries had a strong VSMC proliferation and developed considerable neointimal thickening. The area of the neointima was 0.186 +/- 0.02 mm : (SEM) with a range of 0.10 to 0.28. Luminal patentency was correspondingly narrowed by 40 +/- 4% (range 21 to 63), Figure 8C. The intima:media ratio was 1.51 +/- 0.1 (range 0.87 to 2.17) . These results are similar to those obtained previously in saline treated control vessels. In contrast, Ad-CMVgaxHA treatment markedly reduced the pathologic response to balloon injury. For the Ad-CMVgaxHA treated vessels, mean area of neointimal lesions was 0.076 +/- 0.02 mm 2 (range 0 to 0.19), luminal narrowing was reduced to 17.5 +/- 5%. Satistical analysis confirmed that Ad-CMVgaxHA treatment significantly inhibited the development of intimal thickening relative to the Ad-RSVβ-Gal controls . Specifically, treatment with Ad-CMVgaxHA decreased the intima:media ratio by 69%, the intimal area by 59% and the luminal narrowing by 56% (Figures 8A and 8B) . The remarkable effect on intimal hyperplasia is further emphasized by the results obtained with cross sections of control (Figure 9A) or treated (Figure 9B) animals. This example demonstrates the very efficient in vivo growth arrest activity of the Ad-CMVgaxHA construct. This activity is very specific and not observed in control animals . The results presented clearly show the therapeutic activity of the Ad-CMVgaxHA on vascular morphology, and in particular, on hyperplasia which is associated with post- angioplasty restenosis. The use of a virus, such as an adenovirus to transfer the Gax gene in vivo is particularly efficient. This method is further advantageous since it is based on a gene replacement approach. This method is unique in that it combines both delivery efficiency and therapeutic gene displaying two therapeutic properties: growth arrest and constitutive expression in vascular system. The Gax gene transfer according to this invention induces a specific regression of hyperproliferative disorder in vascular vessel and thereby, normalizes arterial functions. Local Gax gene transfer of the invention is also particularly advantageous in that it does not interfere with the re-endothelization process following lesion of the artery. Furthermore, in addition to a direct impact on cell proliferation and vascular morphology, the gax gene transfer according to the invention may also exert a beneficial indirect effect on the synthesis of extracellular matrix and on remodeling. These results clearly show that the Gax gene transfer according to the invention is a powerful new approach for the treatment of vascular lesions following angioplasty. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: NAME: CASE WESTERN RESERVE UNIVERSITY STREE : CITY: Cleveland STATE: Ohio COUNTRY: USA POSTAL CODE: 44106 (i) APPLICANT: NAME: BRANELLEC, Didier STREET: 1, Rue Saint-Benoit CITY: 94210 La Varenne-Saint Hilaire STATE: COUNTRY: France POSTAL CODE: (i) APPLICANT: NAME: WALSH, Kenneth STREET: 207 Judy Farm Road CITY: Carlisle STATE: Massachusetts COUNTRY: USA POSTAL CODE: 01741 (i) APPLICANT: NAME: ISNER, Jeffrey M. STREET: 34 Brenton Road CITY: Weston STATE: Massachusetts COUNTR : USA POSTAL CODE: 02193 (ii) TITLE OF INVENTION: VIRAL VECTORS AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS, IN PARTICULAR RESTENOΞIS (iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Rhone-Poulenc Rorer Inc. (B) STREET: 500 Arcola Rd. 3C43 (C) CITY: Collegeville (D) STATE: PA (E) COUNTRY: USA (F) ZIP: 19426 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: FR 95-04234 (B) FILING DATE: 31-MAR-1995 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Savitzky, Martin F. (B) REGISTRATION NUMBER: 29,699 (C) REFERENCE/DOCKET NUMBER: ST95022-US (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (610)454-3816 (B) TELEFAX: (610)454-3808 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 : Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Gly Gly Pro

Claims: CLAIMS 1. Defective recombinant virus which contains at least one inserted gene encoding all or part of the GAX protein or of a variant of this protein. 2. Virus according to claim 1, characterized in that it lacks the regions of its genome which are necessary for its replication in the infected cell. 3. Virus according to claim 1 or 2, characterized in that it is an adenovirus, preferably of the Ad 5 or Ad 2 type. 4. Virus according to claim 1 or 2, characterized in that it is an adenovirus of animal, preferably canine, origin. 5. Virus according to one of claims 1 to 4, characterized in that the inserted gene encodes all or part of the rat GAX protein or of a variant of this protein. 6. Virus according to claim 5, characterized in that the inserted gene encodes the rat GAX protein or its human homologue. 7. Virus according to one of claims 1 to 6, characterized in that the inserted gene is a cDNA. 8. Virus according to one of claims 1 to 6, characterized in that the inserted gene is a gDNA. 9. Virus according to one of claims 1 to 8, characterized in that the inserted gene includes sequences which enable it to be expressed in the infected cell. 10. Virus according to one of claims 1 to 9, characterized in that the inserted gene includes a signal sequence which directs the synthesized polypeptide into the secretory pathways of the target cell. 11. Adenovirus according to claim 3 or 4, characterized in that it contains a deletion of all or part of the El region. 12. Adenovirus according to claim 11, characterized in that it additionally contains a deletion of all or part of the E4 region. 13. Virus according to claim 1 or 2, characterized in that it is an adeno-associated virus (AAV) . 14. Virus according to claim 1 or 2, characterized in that it is a retrovirus. 15. Use of a virus according to one of claims 1 to 14, for preparing a pharmaceutical composition which is intended for the treatment or prevention of pathologies which are linked to hyperproliferative disorders . 16. Use according to claim 15, for preparing a pharmaceutical composition which is intended for the treatment of restenosis. 17. Pharmaceutical composition which comprises one or more defective recombinant viruses according to one of claims 1 to 14. 18. Pharmaceutical composition according to claim 17, characterized in that it is in injectable form and in that it comprises from 10" to 10 14 pfu of adenovirus/ml. 19. Pharmaceutical composition according to claim 18, characterized in that it comprises a recombinant adenovirus which is saturated into a hydrogel. AMENDED CLAIMS [received by the International Bureau on 16 August 1996 (16.08.96); original claims 5, 7-11, 15 and 17 amended; remaining claims unchanged (3 pages)] 1. Defective recombinant virus which contains at least one inserted gene encoding all or part of the GAX protein or of a variant of this protein. 2. Virus according to claim 1, characterized in that it lacks the regions of its genome which are necessary for its replication in the infected cell. 3. Virus according to claim 1 or 2, characterized in that it is an adenovirus, preferably of the Ad 5 or Ad 2 type. 4. Virus according to claim 1 or 2, characterized in that it is an adenovirus of animal, preferably canine, origin. 5. Virus according to one of claims 1 or 2, characterized in that the inserted gene encodes all or part of the rat GAX protein or of a variant of this protein. 6. Virus according to claim 5, characterized in that the inserted gene encodes the rat GAX protein or its human homologue. 7. Virus according to one of claims 1 or 2, characterized in that the inserted gene is a cDNA. 8. Virus according to one of claims 1 or 2, characterized in that the inserted gene is a gDNA. 9. Virus according to one of claims 1 or 2, characterized in that the inserted gene includes sequences which enable it to be expressed in the infected cell. 10. Virus according to one of claims 1 or 2, characterized in that the inserted gene includes a signal sequence which directs the synthesized polypeptide into the secretory pathways of the target cell. 11. Adenovirus according to claim 3, characterized in that it contains a deletion of all or part of the El region. 12. Adenovirus according to claim 11, characterized in that it additionally contains a deletion of all or part of the E4 region. 13. Virus according to claim 1 or 2, characterized in that it is an adeno-associated virus (AAV) . 14. Virus according to claim 1 or 2, characterized in that it is a retrovirus. 15. Use of a virus according to one of claims 1 or 2, for preparing a pharmaceutical composition which is intended for the treatment or prevention of pathologies which are linked to hyperproliferative disorders. 16. Use according to claim 15, for preparing a pharmaceutical composition which is intended for the treatment of restenosis. 17. Pharmaceutical composition which comprises one or more defective recombinant viruses according to one of claims 1 or 2. 18. Pharmaceutical composition according to claim 17, characterized in that it is in injectable form and in that it comprises from 10" to 10 14 pfu of adenovirus/ml . 19. Pharmaceutical composition according to claim 18, characterized in that it comprises a recombinant adenovirus which is saturated into a hydrogel.

Inventors: BRANELLEC DIDIER, DENEFLE PATRICE, ISNER JEFFREY M, WALSH KENNETH, BRANELLEC, DIDIER, DENEFLE, PATRICE, ISNER, JEFFREY, M., WALSH, KENNETH
Applicants: BRANELLEC DIDIER, DENEFLE PATRICE, ISNER JEFFREY M, UNIV CASE WESTERN RESERVE, WALSH KENNETH, BRANELLEC, DIDIER, CASE WESTERN RESERVE UNIVERSITY, DENEFLE, PATRICE, ISNER, JEFFREY, M., WALSH, KENNETH
Application year: 1996
Main classification: C07H21
IPC codes: A61K9, A61K35, A61K38, A61K48, A61P9, A61P43, C07K14, C12N7, C12N15